<DOC>
	<DOCNO>NCT01226953</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity booster dose two commercially available vaccine use prevent Haemophilus influenzae type b infection child 365-569 day age</brief_summary>
	<brief_title>Immunogenicity Safety Booster Dose Monovalent Glycoprotein-Conjugated ( Diptheria Toxin -CRM197 ) Hib Vaccine 365-569 Days Old Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants 365569 day age . Subjects already receive booster dose Hib vaccine . History serious reaction ( ) follow vaccination . Any vaccination within 7 day study vaccination . Known suspected immune impairment .</criteria>
	<gender>All</gender>
	<minimum_age>365 Days</minimum_age>
	<maximum_age>569 Days</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Haemophilus influenzae type b ( Hib )</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Anti-PRP antibody</keyword>
</DOC>